Form 4: Teva Pharmaceutical Industries Executive Matthew Shields Acquires Restricted Share Units

EVP of Global Operations at Teva Pharmaceutical Industries, Matthew Shields, reports acquisition of restricted share units convertible to ordinary shares.

Summary

• Matthew Shields, EVP of Global Operations at Teva Pharmaceutical Industries, filed a Form 4 indicating changes in beneficial ownership.
• On June 3, 2024, Shields acquired 64,782 restricted share units (RSUs).
• Each RSU represents a contingent right to receive one ordinary share or the cash value of one ordinary share.
• The RSUs vest in four tranches: 16,195 on each of June 3, 2025, June 3, 2026, and June 3, 2027, and 16,197 on June 3, 2028.
• Following the transaction, Shields directly owns 64,782 ordinary shares represented by the RSUs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of RSUs is a standard practice, and the vesting schedule indicates a long-term commitment from the executive. There are no immediate negative implications.

Positives

• The acquisition of restricted share units by a top executive signals confidence in the company's future performance.
• The vesting schedule incentivizes long-term commitment from the executive.

Future Outlook

The vesting schedule suggests a multi-year commitment from the executive, aligning his interests with the long-term performance of Teva Pharmaceutical Industries.

Industry Context

In the pharmaceutical industry, granting restricted share units is a common practice to incentivize and retain key executives, aligning their interests with shareholder value and long-term company performance. This is a standard compensation strategy used by companies like Pfizer, Novartis, and Johnson & Johnson.

Comparison to Industry Standards

• Companies like Pfizer, Novartis, and Johnson & Johnson commonly use restricted share units as part of their executive compensation packages.
• The vesting schedule of Teva's RSUs is fairly standard, with vesting occurring over a period of several years to incentivize long-term commitment.
• The specific number of RSUs granted depends on the executive's role, performance, and the company's overall compensation strategy, making direct comparisons challenging without more detailed information.

Stakeholder Impact

• Shareholders may view the RSU grant positively, as it aligns executive interests with long-term company performance.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates